Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary

William B Feldman; Jerry Avorn; Aaron S Kesselheim

doi:10.1001/jamainternmed.2019.5337

Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary

JAMA Intern Med. 2020 Mar 1;180(3):454-456. doi: 10.1001/jamainternmed.2019.5337.

Authors

William B Feldman^{1

2}, Jerry Avorn¹, Aaron S Kesselheim¹

Affiliations

¹ Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Abstract

This study examines the estimated cost of asthma inhalers for individuals treated under Medicare Part B compared with those treated under the Veterans Affairs Health System, taking into account separate approaches to price negotiation.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Cost Savings*
Drug Costs*
Humans
Medicare Part D / economics*
Nebulizers and Vaporizers / economics*
Prescriptions
Vereinigte Staaten

Grants and funding

T32 HL007633/HL/NHLBI NIH HHS/United States